Download Sample
Add to CartGlobal Ascites Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Types;
Transudative Ascites and Exudate Ascites.By Diagnosis;
Ultrasound , CT Scan , Laparoscopy, and Angiography.By Treatment;
Surgeries, Medication, and Paracentesis.By End User;
Hospitals & Clinics , Ambulatory Surgical Center, and Diagnostic Centres.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Ascites Market (USD Million), 2021 - 2031
In the year 2024, the Global Ascites Market was valued at USD 3,239.81 million. The size of this market is expected to increase to USD 4,263.37 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.0%.
The global ascites market is witnessing significant growth and evolution driven by various factors, including increasing incidences of liver cirrhosis, cancer, heart failure, and other diseases leading to ascites accumulation. Ascites, characterized by the accumulation of fluid in the abdominal cavity, presents considerable challenges in patient management and quality of life. This condition often arises as a complication of advanced liver disease, such as cirrhosis, where the liver's ability to function is severely compromised. Additionally, ascites can result from malignancies affecting various organs, such as ovarian, pancreatic, or gastrointestinal cancers.
The rising prevalence of chronic liver diseases, fueled by factors like alcohol abuse, hepatitis infections, and metabolic disorders, is a primary driver behind the expanding ascites treatment market. Moreover, the aging population worldwide contributes significantly to the increasing incidence of ascites, as age-related changes in liver function and comorbidities become more prevalent. These demographic shifts, coupled with lifestyle changes and environmental factors, underscore the pressing need for effective therapies and management strategies for ascites.
Advancements in medical technology and the pharmaceutical sector have led to the development of innovative treatment options for ascites management. Therapeutic interventions range from dietary modifications and diuretic medications to more invasive procedures such as paracentesis and transjugular intrahepatic portosystemic shunt (TIPS) placement. Additionally, the emergence of novel pharmaceutical agents targeting the underlying mechanisms of fluid retention and hepatic dysfunction holds promise for improving patient outcomes and reducing the burden of ascites-related complications.
The growing emphasis on personalized medicine and precision healthcare is driving research efforts towards identifying biomarkers, genetic factors, and molecular pathways associated with ascites development and progression. This deeper understanding of the disease mechanisms not only facilitates early diagnosis and risk stratification but also opens avenues for the development of targeted therapies tailored to individual patient profiles.
Despite these advancements, challenges persist in the ascites treatment landscape, including limited access to healthcare services, disparities in disease management practices, and the high economic burden associated with prolonged hospitalizations and disease complications. Addressing these challenges requires a comprehensive approach involving healthcare stakeholders, policymakers, and research institutions to promote awareness, improve healthcare infrastructure, and foster innovation in ascites management.
The global ascites market is characterized by a dynamic interplay of disease burden, technological innovation, and evolving treatment paradigms. With a growing emphasis on holistic patient care and therapeutic advancements, the future holds promising prospects for improving outcomes and enhancing the quality of life for individuals affected by ascites and related conditions.
Global Ascites Market Recent Developments
-
In June 2021, Johnson & Johnson entered a partnership with Arbutus Biopharma to develop and commercialize an ascites drug candidate, as announced on their website. Under this agreement, both companies combined their assets, aiming to achieve significant market advancements through joint efforts.
-
In March 2020, Novartis submitted its New Drug Application (NDA) for its ascites drug candidate to the FDA, marking a significant step forward in developing a therapy for this condition.
Segment Analysis
The global ascites market is segmented by types, which includes cirrhotic ascites, malignant ascites, and cardiac ascites, among others. Cirrhotic ascites, the most common form of ascites, occurs due to liver cirrhosis and is often associated with chronic liver diseases, where fluid accumulates in the abdomen due to poor liver function. Malignant ascites is caused by cancers, particularly ovarian, gastrointestinal, and liver cancers, leading to the accumulation of fluid in the peritoneal cavity. Cardiac ascites, less common, is associated with heart failure, where poor heart function leads to fluid buildup in the abdomen. The increasing prevalence of liver diseases, cancers, and heart conditions is expected to drive growth in the ascites market across these various types.
The market is further segmented by diagnosis, which includes ultrasound, CT scans, MRI, and paracentesis. Ultrasound is the most widely used diagnostic tool for ascites, offering a non-invasive and cost-effective method to detect fluid accumulation. CT scans and MRI are more advanced imaging techniques that provide detailed cross-sectional images of the abdomen, helping to identify the underlying cause of ascites. Paracentesis, a procedure where fluid is drawn from the abdomen using a needle, not only helps confirm the diagnosis but also provides information on the composition of the fluid, which can be useful in determining whether the ascites is benign or malignant. These diagnostic tools are crucial in the timely identification and management of ascites, and their usage is increasing as awareness and diagnosis of liver diseases and cancers rise globally.
The treatment segment includes diuretics, paracentesis, albumin infusions, and surgical interventions. Diuretics are commonly used to manage ascites, helping the body remove excess fluid, particularly in cases of cirrhotic ascites. In more severe cases, paracentesis is performed to drain the excess fluid from the abdomen, providing immediate relief to patients. Albumin infusions are used in conjunction with paracentesis to maintain blood pressure and reduce the risk of complications. For malignant ascites, treatments may involve chemotherapy or surgical interventions, including the insertion of shunts or the use of peritoneovenous shunting to help control fluid buildup. End-users of ascites treatments include hospitals, clinics, and homecare settings. Hospitals and clinics are the primary end-users of diagnostic and treatment services for ascites, given the need for specialized equipment and trained healthcare professionals. In contrast, homecare settings are growing due to the increasing prevalence of chronic conditions that require ongoing management, particularly for patients with cirrhotic or stable ascites. Geographically, North America leads the ascites market, driven by advanced healthcare infrastructure, a high incidence of liver disease and cancer, and the availability of advanced diagnostic and treatment options. Europe follows closely, with increasing healthcare investments and rising cancer rates. The Asia-Pacific region is witnessing rapid market growth due to improving healthcare access, rising liver disease prevalence, and growing awareness of ascites diagnosis and treatment.
Global Ascites Market Segment Analysis
In this report, the Global Ascites Market has been segmented by Types, Diagnosis, Treatment, End User and Geography.
Global Ascites Market, Segmentation by Types
The Global Ascites Market has been segmented by Types into Transudative Ascites and Exudate Ascites.
Transudative ascites occurs when fluid leaks into the abdominal cavity due to systemic factors such as liver cirrhosis, heart failure, or hypoalbuminemia. Liver cirrhosis, in particular, is a significant contributor to transudative ascites, accounting for a substantial portion of cases worldwide. As cirrhosis progresses, it leads to portal hypertension, impairing the liver's ability to maintain fluid balance and resulting in the accumulation of ascitic fluid.
Exudative ascites, on the other hand, typically arises from local factors such as infection, inflammation, or malignancy affecting the peritoneal cavity. Conditions such as peritoneal carcinomatosis, tuberculosis peritonitis, and pancreatitis can trigger the formation of exudative ascites through various mechanisms, including increased vascular permeability and lymphatic obstruction.
The management of ascites depends on the underlying cause and severity of the condition. Treatment strategies often aim to alleviate symptoms, reduce fluid accumulation, and address the underlying disease process. Diuretics, paracentesis, and dietary modifications are commonly employed in the management of ascites, with more advanced interventions such as transjugular intrahepatic portosystemic shunt (TIPS) procedures or liver transplantation reserved for refractory cases or those with severe liver disease.
There has been growing research interest and pharmaceutical development focused on addressing the underlying mechanisms driving ascites formation, particularly in the context of liver cirrhosis. Targeted therapies aimed at modulating portal hypertension, improving liver function, and reducing inflammation hold promise for improving outcomes in patients with ascites.
Despite advancements in treatment modalities, ascites remains a significant clinical challenge associated with considerable morbidity and mortality, particularly in patients with advanced liver disease. Further research into the pathophysiology of ascites and the development of novel therapeutic approaches are needed to improve outcomes and quality of life for affected individuals worldwide.
Global Ascites Market, Segmentation by Diagnosis
The Global Ascites Market has been segmented by Diagnosis into Ultrasound , CT Scan , Laparoscopy and Angiography.
Ultrasound remains a cornerstone in the diagnosis of ascites due to its non-invasive nature, cost-effectiveness, and widespread availability. It enables clinicians to visualize the presence and extent of fluid accumulation within the peritoneal cavity, aiding in both diagnosis and monitoring of the condition.
Complementing ultrasound, CT scan (computed tomography) offers detailed cross-sectional imaging, providing valuable insights into the underlying causes of ascites, such as liver cirrhosis, malignancies, or infections. Its ability to detect subtle abnormalities and delineate anatomical structures makes it a valuable tool in the diagnostic algorithm for ascites.
Laparoscopy, although more invasive compared to ultrasound and CT scan, offers direct visualization of the peritoneal cavity, allowing for precise identification of ascitic fluid and assessment of its characteristics. This surgical procedure not only aids in diagnosis but also facilitates therapeutic interventions such as peritoneal fluid drainage or tissue biopsy if needed.
In select cases where conventional imaging modalities yield inconclusive results, angiography may be employed to further delineate the vascular anatomy and identify potential sources of fluid leakage contributing to ascites. While less commonly utilized than ultrasound or CT scan, angiography serves as a valuable adjunctive tool in specific diagnostic scenarios.
The integration of various diagnostic modalities, including ultrasound, CT scan, laparoscopy, and angiography, enables comprehensive evaluation and management of ascites, thereby improving patient outcomes and quality of care. As technology continues to advance, further innovations in diagnostic imaging are expected to enhance the precision and efficiency of ascites diagnosis in the future.
Global Ascites Market, Segmentation by Treatment
The Global Ascites Market has been segmented by Treatment into Surgeries, Medication and Paracentesis.
Surgical interventions play a crucial role in managing ascites, especially in cases where conservative measures prove ineffective. Procedures like transjugular intrahepatic portosystemic shunt (TIPS) and peritoneovenous shunting help alleviate symptoms by redirecting the excess fluid away from the abdominal cavity, thereby reducing pressure and discomfort. However, these surgeries may not be suitable for all patients and carry risks, including infection and bleeding.
Medication remains a cornerstone in the management of ascites, with diuretics being the primary pharmacological approach. Diuretics help the body excrete excess fluid through urine, thereby reducing the volume of ascitic fluid. While effective, long-term use of diuretics may lead to electrolyte imbalances and renal dysfunction, necessitating careful monitoring and dose adjustments.
Paracentesis, a minimally invasive procedure involving the drainage of ascitic fluid from the abdominal cavity, provides rapid relief from symptoms such as abdominal distention and discomfort. It is often performed in conjunction with albumin infusion to prevent complications such as hypotension and renal impairment. Paracentesis offers short-term relief and may need to be repeated regularly depending on the underlying cause of ascites.
In addition to these treatment modalities, ongoing research is focused on developing novel therapies targeting the underlying mechanisms of ascites formation, including inflammation, fluid imbalance, and impaired liver function. The emergence of combination therapies and targeted drug delivery systems holds promise for improving outcomes and enhancing the quality of life for patients with ascites. However, challenges such as drug resistance and limited treatment options for refractory ascites underscore the need for continued innovation and investment in this field.
Global Ascites Market, Segmentation by End User
The Global Ascites Market has been segmented by End User into Hospitals & Clinics , Ambulatory Surgical Center and Diagnostic Centres.
The global ascites market is witnessing significant growth, fueled by a range of end users catering to the needs of patients. Hospitals and clinics stand as pivotal pillars within this market landscape, offering comprehensive care and treatment facilities for individuals afflicted by ascites. These institutions provide a multidisciplinary approach, combining medical expertise, advanced diagnostic tools, and therapeutic interventions to manage the condition effectively.
Aambulatory surgical centers play a crucial role in addressing the needs of ascites patients, particularly those requiring specialized procedures or interventions. These centers offer a convenient and efficient alternative to traditional hospital settings, often providing outpatient procedures that minimize the disruption to patients' daily lives while ensuring high-quality care delivery.
Diagnostic centers serve as essential entities within the ascites market, offering a range of imaging and laboratory services crucial for accurate diagnosis, disease monitoring, and treatment planning. These facilities utilize state-of-the-art technology and employ skilled professionals to conduct various diagnostic tests, such as ultrasound, CT scans, and laboratory analyses, enabling prompt identification and management of ascites-related complications.
Hospitals, ambulatory surgical centers, and diagnostic centers form a cohesive ecosystem aimed at addressing the multifaceted needs of ascites patients. Their collaborative efforts underscore the importance of a comprehensive and integrated approach to managing this challenging condition, ultimately improving patient outcomes and enhancing the overall quality of care across the global ascites market.
Global Ascites Market, Segmentation by Geography
In this report, the Global Ascites Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Ascites Market Share (%), by Geographical Region, 2024
The global ascites market is expected to witness significant growth from 2020 to 2030 across various geographical regions including North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. North America, being a mature healthcare market with advanced medical infrastructure and high healthcare expenditure, is anticipated to dominate the ascites market during this period. Factors such as the rising prevalence of liver cirrhosis and other liver-related disorders, coupled with increasing awareness regarding treatment options, are likely to drive market growth in this region.
Europe is also expected to witness substantial growth in the ascites market, owing to factors such as the increasing incidence of liver diseases and the presence of key market players focusing on product development and strategic collaborations. Moreover, the growing elderly population in countries like Germany, France, and the UK is expected to contribute to market growth as the elderly are more prone to liver diseases leading to ascites.
In the Asia Pacific region, rapid urbanization, changing lifestyles, and increasing alcohol consumption are contributing to the rising prevalence of liver diseases, thus driving the demand for ascites treatment. Additionally, improving healthcare infrastructure, growing healthcare expenditure, and increasing awareness regarding liver diseases and their management are expected to fuel market growth in this region.
The Middle East and Africa region is anticipated to witness steady growth in the ascites market during the forecast period. Factors such as the high prevalence of hepatitis B and C, as well as other liver diseases, coupled with improving healthcare infrastructure and rising healthcare expenditure, are likely to drive market growth in this region.
Latin America is also expected to offer lucrative growth opportunities in the ascites market, driven by factors such as increasing alcohol consumption, rising prevalence of liver diseases, and improving healthcare infrastructure in countries like Brazil and Mexico. However, challenges such as limited access to healthcare facilities and low awareness regarding liver diseases may hinder market growth to some extent in this region.
The global ascites market is poised for significant growth from 2020 to 2030 across various geographical regions, driven by factors such as the increasing prevalence of liver diseases, growing elderly population, improving healthcare infrastructure, and rising awareness regarding the management of ascites.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Ascites Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Genetic Factors
- Molecular Pathways
- Personalized Medicine
-
Healthcare Infrastructure -The global ascites market's healthcare infrastructure is a critical aspect that significantly influences the diagnosis, treatment, and management of this condition. Ascites, often associated with serious underlying diseases such as liver cirrhosis or cancer, requires a robust healthcare system capable of providing timely and comprehensive care to patients worldwide.
The availability of medical facilities equipped with advanced diagnostic and therapeutic capabilities is essential for effectively managing ascites. Hospitals with specialized gastroenterology, hepatology, or oncology departments play a central role in diagnosing the underlying cause of ascites and initiating appropriate treatment interventions. Access to experienced healthcare professionals, including gastroenterologists, hepatologists, oncologists, and interventional radiologists, is crucial for delivering optimal care to patients with ascites.
Advanced diagnostic infrastructure is necessary for accurate and timely diagnosis of ascites and its underlying causes. Medical imaging facilities offering ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI) play a vital role in detecting ascites, assessing its severity, and identifying any associated complications such as hepatocellular carcinoma or portal hypertension. Additionally, laboratories capable of performing biochemical analyses of ascitic fluid obtained through paracentesis contribute to refining the diagnosis and guiding treatment decisions.
The availability of a diverse range of treatment modalities is essential for effectively managing ascites based on its underlying etiology and severity. Healthcare facilities need access to medications such as diuretics for fluid management, as well as facilities for performing invasive procedures like paracentesis or transjugular intrahepatic portosystemic shunt (TIPS) placement when indicated. Surgical expertise may be required for managing complications of ascites such as spontaneous bacterial peritonitis or refractory ascites.
Investment in research and development infrastructure is crucial for advancing the understanding of ascites pathophysiology, identifying novel therapeutic targets, and developing innovative treatment approaches. Collaboration between academic institutions, pharmaceutical companies, and healthcare organizations fosters the discovery of new drugs, diagnostic biomarkers, and medical devices aimed at improving the management of ascites and enhancing patient outcomes.
Government policies, healthcare regulations, and funding mechanisms significantly impact the accessibility and affordability of ascites management services. Adequate healthcare financing, reimbursement policies for diagnostic tests and treatment procedures, and equitable distribution of healthcare resources are essential for ensuring that patients with ascites receive timely and appropriate care irrespective of their socioeconomic status or geographical location.
The healthcare infrastructure supporting the global ascites market encompasses a wide range of medical facilities, diagnostic capabilities, treatment modalities, research initiatives, and healthcare policies. Strengthening this infrastructure through investments in healthcare delivery systems, technology innovation, research funding, and policy reforms is essential for addressing the challenges posed by ascites and improving patient outcomes on a global scale.
Restraints:
- Limited treatment options
- High economic burden
- Healthcare disparities
-
Access to healthcare services -Access to healthcare services plays a crucial role in addressing the challenges associated with ascites on a global scale. The availability and affordability of healthcare services significantly impact the diagnosis, management, and outcomes of patients with ascites, particularly in regions with limited resources or healthcare infrastructure.
Increasing awareness among healthcare providers and the general population about the signs, symptoms, and risk factors of ascites can facilitate early detection and intervention. Educational initiatives targeting primary care physicians, nurses, and allied healthcare professionals can improve the timely referral of patients to specialized care.
Investment in healthcare infrastructure, including the expansion of medical facilities, the training of healthcare personnel, and the procurement of essential medical equipment and supplies, is essential for improving access to diagnosis and treatment services for ascites.
Implementing policies to enhance health insurance coverage and financial assistance programs can help mitigate the economic burden of ascites-related healthcare expenses for patients and their families. This includes subsidizing the cost of diagnostic tests, medications, and procedures, as well as providing support for transportation and accommodation for patients requiring specialized care in distant healthcare facilities.
Leveraging telemedicine and remote monitoring technologies can enhance access to healthcare services for patients with ascites, particularly those residing in rural or underserved areas. Virtual consultations, remote monitoring of vital signs and fluid status, and tele-education initiatives can improve patient outcomes while reducing the need for frequent in-person visits to healthcare facilities.
Engaging community health workers, patient advocacy groups, and non-governmental organizations (NGOs) in ascites awareness campaigns, screening programs, and patient support initiatives can help reach vulnerable populations and facilitate access to healthcare services at the grassroots level.
These key areas, policymakers, healthcare providers, and stakeholders can work together to improve access to healthcare services for individuals affected by ascites, ultimately reducing the burden of this debilitating condition on a global scale.
Opportunities:
- Therapeutic Innovation
- Precision Medicine
- Biomarker Identification
-
Disease Management Practices -In managing ascites, a multifaceted approach is essential, encompassing both disease-specific interventions and supportive care measures. The global ascites market reflects a spectrum of disease management practices aimed at alleviating symptoms, addressing underlying causes, and improving overall patient outcomes. Key components of disease management in ascites include:
Ascites commonly arises as a complication of liver cirrhosis, heart failure, malignancies, or other conditions. Targeted management of the underlying etiology is fundamental in controlling ascites progression. Therapeutic strategies may involve medications to manage liver disease, such as diuretics or antiviral agents, or interventions like chemotherapy for ascites related to cancer.
Central to ascites management is fluid regulation to prevent excessive accumulation in the abdominal cavity. Diuretics, particularly spironolactone and furosemide, are commonly prescribed to promote diuresis and reduce fluid retention. Careful monitoring of electrolyte levels and renal function is crucial to prevent complications associated with diuretic therapy.
Therapeutic paracentesis involves the removal of excess ascitic fluid from the peritoneal cavity to relieve symptoms of abdominal distension and discomfort. This procedure may be performed as needed or on a regular schedule, depending on the severity and recurrence of ascites. Paracentesis also serves as a diagnostic tool, enabling analysis of ascitic fluid composition to guide further management.
Dietary sodium restriction is often recommended to mitigate fluid retention and optimize diuretic therapy effectiveness. Patients with ascites are advised to limit sodium intake and adhere to a balanced diet rich in fruits, vegetables, and lean proteins. Nutrition counseling may be beneficial in ensuring adequate nutrient intake while minimizing fluid overload.
Ascites predisposes individuals to various complications, including spontaneous bacterial peritonitis (SBP), hepatic encephalopathy, and renal dysfunction. Prompt recognition and management of these complications are critical in preventing disease progression and improving survival outcomes. Antibiotic prophylaxis, lactulose therapy, and supportive measures are commonly employed to mitigate complications associated with ascites.
Patients with end-stage liver disease and refractory ascites, liver transplantation represents a definitive therapeutic option. Transplantation offers the potential for long-term survival and resolution of ascites by addressing the underlying liver pathology. However, access to transplantation may be limited by factors such as organ availability and patient candidacy criteria.
Lifestyle interventions, including alcohol cessation, smoking cessation, and weight management, play a pivotal role in mitigating risk factors associated with ascites development and progression. Patient education and adherence to healthy lifestyle practices are integral components of long-term disease management.
The global ascites market encompasses a comprehensive array of disease management practices aimed at addressing the underlying causes, alleviating symptoms, and improving the quality of life for individuals affected by ascites. Multidisciplinary collaboration among healthcare professionals, including hepatologists, oncologists, gastroenterologists, and supportive care teams, is essential in delivering optimal care tailored to the individual needs of patients with ascites.
Competitive Landscape Analysis
Key players in Global Ascites Market include, Sequana Medical.
- Sequana Medical
- BioVie
- PharmaCyte Biotech Inc.
- Fresenius SE & Co. KGaA
- BD
- GI Supply
- Medtronic
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Types
- Market Snapshot, By Diagnosis
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Ascites Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Genetic Factors
-
Molecular Pathways
-
Personalized Medicine
-
Healthcare Infrastructure
-
- Restraints
-
Limited treatment options
-
High economic burden
-
Healthcare disparities
-
Access to healthcare services
-
- Opportunities
-
Therapeutic Innovation
-
Precision Medicine
-
Biomarker Identification
-
Disease Management Practices
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Ascites Market, By Types, 2021 - 2031 (USD Million)
- Transudative Ascites
- Exudate Ascites
- Global Ascites Market, By Diagnosis, 2021 - 2031 (USD Million)
- Ultrasound
- CT Scan
- Laparoscopy
- Angiography
- Global Ascites Market, By Treatment, 2021 - 2031 (USD Million)
- Surgeries
- Medication
- Paracentesis
- Global Ascites Market, By End User, 2021 - 2031 (USD Million)
- Hospitals & Clinics
- Ambulatory Surgical Center
- Diagnostic Centres
- Global Ascites Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Ascites Market, By Types, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Sequana Medical
- BioVie
- PharmaCyte Biotech Inc.
- Fresenius SE & Co. KGaA
- BD
- GI Supply
- Medtronic
- Company Profiles
- Analyst Views
- Future Outlook of the Market